Source: FLCCC

video

Dr. Kory’s testimony on December 8, 2020:

Appearing as a witness Tuesday morning before the Senate Committee on Homeland Security and Governmental Affairs—which held a hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution”— Dr. Pierre Kory, President of the Frontline COVID-19 Critical Care Alliance (FLCCC), called for the government to swiftly review the already expansive and still rapidly emerging medical evidence on Ivermectin.

The data shows the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover.

Dr. Kory testified that Ivermectin is effectively a “miracle drug” against COVID-19 and called upon the government’s medical authorities — the NIH, CDC, and FDA—to urgently review the latest data and then issue guidelines for physicians, nurse-practitioners, and physician assistants to prescribe Ivermectin for COVID-19.

Get all relevant information on the FLCCC Alliance’s prophylaxis and treatment protocols for COVID-19 on flccc.net






Related: The FLCCC Alliance— On a mission to Save Thousands & Slow the Pandemic

COVID-19: A realistic approach to community management – HCQ & IVM in concert with vaccination

Emeritus Professor Robert Clancy responds to MP Craig Kelly’s hydroxychloroquine & ivermectin comments: Liam Bartlet‪t‬ interview

HCQ and Ivermectin included in multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk COVID-19

Use of Ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt : A randomised clinical trial

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »